Karyopharm and the Multiple Myeloma Research Foundation Announce Panel Discussion Featuring Leading Multiple Myeloma Thought ...
November 30 2016 - 7:30AM
Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage
pharmaceutical company, together with the Multiple Myeloma Research
Foundation (MMRF), the leading provider of multiple myeloma
research, today announced that Karyopharm will host an investor and
analyst dinner reception featuring a panel discussion with
recognized multiple myeloma (MM) thought leaders and moderated by
Daniel Auclair, PhD, Senior Vice President of Research at the
MMRF. The Karyopharm-sponsored event is scheduled for Monday,
December 5, 2016 from 8:15 - 9:30 p.m. PT, immediately following
formal programming for the 58th American Society of Hematology
(ASH) Annual Meeting.
“Despite recent advances that have substantially
improved the life expectancy of myeloma patients, a cure remains
elusive and treatment gaps persist,” said Dr. Auclair. “We are
encouraged by the growing body of research to suggest that oral
selinexor, alone and in combination with other approved therapies,
represents a potential breakthrough in the treatment of
multi-refractory myeloma patients, where a high unmet medical need
still exists.”
Panel participants scheduled to participate
include:
- Nizar Bahlis, MD, University of Calgary, Southern Alberta
Cancer Research Institute
- Paul G. Richardson, MD, Dana Faber Cancer Institute,
Jerome Lipper Multiple Myeloma Center
- Ravi Vij, MD, MBA, Washington University School of Medicine in
St. Louis, Oncology Division
- Dan T. Vogl, MD, Abramson Cancer Center Clinical Research
Unit, University of Pennsylvania
In addition, Michael Kauffman, MD, PhD, CEO
of Karyopharm Therapeutics will be joining.
A live webcast of the presentation will begin at
8:15 p.m. PT and can be accessed under "Events & Presentations"
in the Investors section of the Company's website at
http://investors.karyopharm.com/events.cfm. A replay of the webcast
will be archived on the Company's website for 90 days following the
event.
About the Multiple Myeloma Research
Foundation
The mission of the Multiple Myeloma Research
Foundation (MMRF) is to find a cure for multiple myeloma by
relentlessly pursuing innovation that accelerates the development
of next-generation treatments to extend the lives of patients.
Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and
her twin sister Karen Andrews as a 501(c) (3) nonprofit
organization, the MMRF is a world-recognized leader in cancer
research. Together with its partners, the MMRF has created the only
end-to-end solution in precision medicine and the single largest
genomic dataset in all cancers. The MMRF continues to disrupt the
industry today, as a pioneer and leader at the helm of new research
efforts. Since its inception, the organization has raised over $330
million and directs nearly 90% of the total funds to research and
related programs. To learn more, visit www.themmrf.org
About Karyopharm
Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a
clinical-stage pharmaceutical company focused on the discovery and
development of novel first-in-class drugs directed against nuclear
transport and related targets for the treatment of cancer and other
major diseases. Karyopharm's SINE™ compounds function by binding
with and inhibiting the nuclear export protein XPO1 (or CRM1). The
Company's initial focus is on seeking regulatory approval and
commercialization of its lead drug candidate, oral selinexor
(KPT-330). To date, over 1,800 patients have been treated with
selinexor and it is currently being evaluated in several mid- and
later-phase clinical trials across multiple cancer indications,
including multiple myeloma in combination with low-dose
dexamethasone (STORM) and backbone therapies (STOMP), and in acute
myeloid leukemia (SOPRA), diffuse large B-cell lymphoma (SADAL),
and liposarcoma (SEAL), among others. Karyopharm plans to
initiate a pivotal randomized Phase 3 study of selinexor in
combination with bortezomib (Velcade®) and low-dose dexamethasone
(BOSTON) in patients with multiple myeloma in early 2017. In
addition to single-agent and combination activity against a variety
of human cancers, SINE™ compounds have also shown biological
activity in models of neurodegeneration, inflammation, autoimmune
disease, certain viruses and wound-healing. Karyopharm, which was
founded by Dr. Sharon Shacham, currently has five investigational
programs in clinical or preclinical development. For more
information, please visit www.karyopharm.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the therapeutic potential of and potential clinical
development plans for Karyopharm's drug candidates, including the
timing of initiation of certain trials. Such statements are subject
to numerous important factors, risks and uncertainties that may
cause actual events or results to differ materially from the
Company's current expectations. For example, there can be no
guarantee that any of Karyopharm's SINE™ compounds, including
selinexor (KPT-330), will successfully complete necessary
preclinical and clinical development phases or that development of
any of Karyopharm's drug candidates will continue. Further, there
can be no guarantee that any positive developments in Karyopharm's
drug candidate portfolio will result in stock price appreciation.
Management's expectations and, therefore, any forward-looking
statements in this press release could also be affected by risks
and uncertainties relating to a number of other factors, including
the following: Karyopharm's results of clinical trials and
preclinical studies and the content and timing of decisions made by
the U.S. Food and Drug Administration and other regulatory
authorities. These and other risks are described under the caption
"Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2016, which was filed with the
Securities and Exchange Commission (SEC) on November 7, 2016, and
in other filings that Karyopharm may make with the SEC in the
future. Any forward-looking statements contained in this press
release speak only as of the date hereof, and Karyopharm expressly
disclaims any obligation to update any forward-looking statements,
whether as a result of new information, future events or
otherwise.
Contact:
Justin Renz
(617) 658-0574
jrenz@karyopharm.com
Gina Nugent
(617) 460-3579
nugentcomm@aol.com
Sharon Saias
(203) 652-0211
saiass@themmrf.org
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Karyopharm Therapeutics (NASDAQ:KPTI)
Historical Stock Chart
From Apr 2023 to Apr 2024